Zopiclone Dosage Guide

Zopiclone Dosage Guide

Educational information about common Zopiclone doses, factors that may influence prescribing decisions, and important safety information.

Zopiclone Tablets

What is Zopiclone?

Zopiclone belongs to a group of medicines commonly known as Z-drugs. It is prescribed for the short-term treatment of insomnia and works by affecting brain activity to help promote sleep.

  • Peak blood concentration: approximately 0.5–2 hours
  • Average half-life: around 5 hours
  • Common prescribed strengths: 3.75 mg and 7.5 mg
  • Introduced into clinical practice in the 1980s

Factors That May Influence Dosage

  • Age
  • Liver function
  • Kidney function
  • Body weight
  • Other medicines
  • Existing medical conditions
  • Individual response to treatment

The appropriate dose should always be determined by a qualified healthcare professional.

Common Zopiclone Strengths

StrengthGeneral Information
3.75 mgOften used as a lower-strength option, particularly where a lower dose is considered appropriate by the prescriber.
7.5 mgCommon prescribed adult strength for short-term treatment of insomnia when considered appropriate by the prescriber.
Higher dosesHigher doses may increase the risk of side effects and should only be used if specifically prescribed.

Dose vs Dosage

Dose: the amount of medicine taken at one time.

Dosage: the amount and frequency of medicine taken over a period of time according to the prescribed regimen.

Possible Side Effects

  • Drowsiness
  • Bitter or metallic taste
  • Dry mouth
  • Dizziness
  • Reduced alertness the following day in some people
Important: Seek medical advice promptly if you experience severe or unusual side effects.

Frequently Asked Questions

How long does Zopiclone take to work?

It is generally taken shortly before bedtime and begins to work within a relatively short period for many people.

Can everyone take the same dose?

No. The appropriate dose depends on individual factors and should be determined by a healthcare professional.